Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Radiation Therapy
  •  Ovarian Cancer
  •  Leukemia
  •  Blood Cancer
  •  Endoscopy Methods
  •  Sarcomas
  •  Thoracic Oncology
  •  Paediatric Cancers


Citation: Clin Oncol. 2023;8(1):2021.DOI: 10.25107/2474-1663.2021

Serum Interleukin-6 Levels Correlate with the Efficacy of Antiangiogenic Therapy in Metastatic Colorectal Cancer

Chen Y, Cai H, Liu Y, Zhang Q and Jia HJ

Department of Surgery, Chongqing Medical University, China

*Correspondance to: Hou Jun Jia 

 PDF  Full Text Research Article | Open Access


Background: Identifying predictive indicators before starting treatment can enhance treatment accuracy. This study aims to assess the correlation between IL-6 concentration in the blood and the efficacy of antiangiogenic therapy for liver metastases from colorectal cancer. Methods: In this retrospective study, we examined 53 patients with CRLM who received nonsurgical treatment from June 2017 to June 2023. We collected serum IL-6 levels before starting treatment and evaluated their impact based on consensus guidelines. The ROC curve was used to determine the best cut-off point for IL-6. We compared treatment response rates using chi-square tests and estimated Overall Survival (OS) and Progression-Free Survival (PFS) using Kaplan-Meier and multivariate Cox proportional hazard regression analyses. Results: Out of the total of 53 patients, the median age was 64 years with a standard deviation of 10.2 years. Among them, 24 patients did not receive bevacizumab while the remaining 29 patients received a therapy that included bevacizumab. It was observed that patients who were treated with bevacizumab had a longer Progression-Free Survival (PFS) compared to those who did not receive it (P=0.04). Out of the 24 patients who received chemotherapy alone, 12 had a shorter PFS compared to the remaining 12 who had lower IL-6 levels (P=0.03). Similar differences were not observed in 29 patients receiving bevacizumab combination therapy (P=0.76). Conclusion: Patients with higher levels of IL-6 benefited from antiangiogenic therapy, whereas those with lower levels did not receive the same benefits from bevacizumab.


Colorectal cancer; Bevacizumab; Inflammation; Interleukin-6 (IL-6)

Cite the Article:

Chen Y, Cai H, Liu Y, Zhang Q, Jia HJ. Serum Interleukin-6 Levels Correlate with the Efficacy of Antiangiogenic Therapy in Metastatic Colorectal Cancer. Clin Oncol. 2023;8:2021..

Search Our Journal

Journal Indexed In

Articles in PubMed

Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Research on the Role of Ezrin Gene in the Pathological Process of Cervical Cancer
 Abstract  PDF  Full Text
The Expression and Relationship of Tc17 Cells and Interleukin-27 in Local and Systemic Environment of Nonsmall Cell Lung Cancer
 Abstract  PDF  Full Text
View More...